PRNewsWire
08 Jul 2026, 12:52 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Quest Diagnostics is integrating its Haystack MRD and Comprehensive Genomic Profiling tests into Flatiron Health's OncoEMR via a pilot program. — Direct EHR integration lowers friction for physician ordering, likely increasing test volume and revenue for Quest's high-value oncology segment.
+0.40The integration will provide 4,700 clinicians across 1,600 community-based cancer care locations in the U.S. with access to Quest's services. — This defines a significant total addressable market for the product rollout, supporting long-term growth projections.
+0.30Quest plans to expand the OncoEMR MPI integration to providers nationwide in the second half of 2026. — The nationwide rollout timeline provides a concrete catalyst for future revenue growth and market penetration.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Quest Diagnostics is expanding its oncology test access through a strategic integration with OncoEMR, potentially increasing its reach to 4,700 clinicians.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
18h ago
